A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped UCL CTC were informed by Merck Sharp \& Dohme on 22.08.11 that support for the trial had been withdrawn in light of results from another trial with trial drug.

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Vorinostat
DRUG: Placebo

Sponsor

University College, London

Collaborators

[object Object]